# Limiting AAA With Metformin (LIMIT) Trial

Study · id `cardio:ct-nct04500756` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04500756](<https://clinicaltrials.gov/study/NCT04500756>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT04500756

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 314 participants.

## Technical summary

Registry record NCT04500756. Randomized; triple masking; primary purpose treatment. Start 2022-02-28 (actual); primary completion 2028-06-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 314 participants (planned count; ClinicalTrials.gov record NCT04500756, source copy `cardio:ctgov-nct04500756-2025-04-18`, retrieved 2026-11-18)
- Started: 2022-02-28 (actual) (ClinicalTrials.gov record NCT04500756, source copy `cardio:ctgov-nct04500756-2025-04-18`, retrieved 2026-11-18)
- Primary completion: 2028-06-30 (anticipated) (ClinicalTrials.gov record NCT04500756, source copy `cardio:ctgov-nct04500756-2025-04-18`, retrieved 2026-11-18)
- Completion: 2028-06-30 (anticipated) (ClinicalTrials.gov record NCT04500756, source copy `cardio:ctgov-nct04500756-2025-04-18`, retrieved 2026-11-18)
- Countries: United States (ClinicalTrials.gov record NCT04500756, source copy `cardio:ctgov-nct04500756-2025-04-18`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04500756-2025-04-18`, retrieved 2026-11-18)

## The registry's words

- Brief title: Limiting AAA With Metformin (LIMIT) Trial
- Acronym: LIMIT
- Condition: Abdominal Aortic Aneurysm
- Intervention (Drug): Metformin
- Intervention (Other): Placebo
- Lead sponsor: Stanford University
- Lead sponsor class: OTHER
- Collaborator: Kaiser Permanente
- Collaborator class: OTHER
- Collaborator: VA Palo Alto Health Care System
- Collaborator class: FED
- Collaborator: National Heart, Lung, and Blood Institute (NHLBI)
- Collaborator class: NIH

## Connected pages

- Registry condition terms include this condition: Abdominal aortic aneurysm (`cardio:abdominal-aortic-aneurysm`)
- Registry condition terms include this condition: Aortic aneurysm (`cardio:aortic-aneurysm`)
- Registry lists this organization as the lead sponsor: Stanford University (`cardio:org-stanford-university`)
- Registry lists this organization as a collaborator: Kaiser Permanente (`cardio:org-kaiser-permanente`)
- Registry lists this organization as a collaborator: National Heart, Lung, and Blood Institute (`cardio:nhlbi`)

## Provenance

Content hash: 43b58f85fd8d20baf8d06e20c5e4d2da6237cfbc2157554bedd4e005a2009fc6
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
